Boan Biotech (6955.HK) announced today that the first patient in Phase III clinical trial of its Nivolumab Injection (BA1104) in China has been enrolled. BA1104 is the first biosimilar to Opdivo® to u...
Yantai, September 27, 2023 - The results of a Phase I clinical trial comparing BA1102, a biosimilar candidate developed by Boan Biotech, with the reference drug denosumab (XGEVA®), were recently publi...
Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been administered to the first subject in a Phase I clinical trial. This makes BA1202 the first CEA/CD3 bispe...